NGS and Cancer Biomarker Market Metrics

June 10, 2014
NGS and Cancer Biomarker Market Metrics
The declining costs of NGS are the key driver for its utilization in the clinical setting. [genome.gov]

Enal Razvi, Ph.D.

Gary M. Oosta, Ph.D.

This report represents qualitative and quantitative metrics of the next-generation sequencing (NGS) landscape and frames it into the context of various biomarker classes.

Highlights of this report:

  • The NGS field is expanding and its quantitative penetrance into clinical testing is growing.
  • We present in this report some data illustrating the various disease classes into which NGS-based testing is penetrating—of course oncology is the leader in this space, but other disease classes are being impacted, too.
  • We also present here our analysis of the cancer biomarkers publications landscape, which demonstrates the patterns of penetration of specific biomarker(s) into various cancer classes—this provides the “starting material” for NGS panels that could be designed and validated on clinical samples as a means to develop NGS-based LDTs for different cancer classes.
  • Taken together, these results frame the market trends of NGS traversing from the research community toward clinical deployment and furthermore offer insight into how NGS-based tests may be developed in large numbers and then tested on patient populations to establish their validity and utility.

Click here to download the PDF report.